Beckman Coulter is pleased to highlight results published in the Journal of Clinical Virology that show the company DxN VERIS VERIS CMV Assay is more sensitive, and the DxN VERIS Molecular Diagnostics System has greater ease-of-use benefits, than another commercially available testing system.

Undertaken at the Department of Virology, Toulouse University Hospital, and the Department of Physiopathology, Toulouse Purpan, Unit Inserm U563, Toulouse, France, the study evaluated the analytical characteristics and performance of the fully automated DxN VERIS Molecular Diagnostics System in comparison to results obtained from the Roche COBAS^® Ampliprep™/COBAS^® TaqMan CMV test.

Using 169 plasma samples, that had previously tested CMV-positive with the in-house technique  on whole blood, the study results not only showed the specificity of the VERIS CMV assay was 99%, but also that the VERIS CMV Assay detected 18 more positive samples than COBAS^® Ampliprep™/COBAS^® TaqMan.

The study concluded that the analytical performance of the system was very good especially the sensitivity which was very high and that the VERIS CMV assay provides precise, reproducible results and it satisfies quality requirements for routine monitoring of DNA-CMV in plasma samples.

read the white paper

more about beckman coulter

more news from beckman coulter